Global Cardiac Biomarkers Industry
13:14 ET
LONDON, Sept. 13, 2018 /PRNewswire/ -- This report analyzes the worldwide markets for Cardiac Biomarkers in US$ Thousand by the following Testing Locations: Laboratory Testing, and Point of Care Testing.
Download the full report: https://www.reportbuyer.com/product/5561790
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.
Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 39 companies including many key and niche players such as:
- Abbott Diagnostics, Inc.
- Quidel Corporation
- Beckman Coulter, Inc.
- BG Medicine, Inc.
- biomérieux SA
- Boditech Med Inc.
Download the full report: https://www.reportbuyer.com/product/5561790
CARDIAC BIOMARKERS MCP-1
A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study
Cardiac Biomarkers
Testing Location
Laboratory Testing
Point of Care Testing
Types of Cardiac Biomarkers
Cardiac Troponin
Natriuretic Peptides
BNP (B-type Natriuretic Peptide)
NT-proBNP (N-terminal proBNP)
Others
Creatine Kinase-MB (CK-MB)
Myoglobin
2. INDUSTRY OVERVIEW
A Curtain Raiser
Major Cardiac Markers and their Properties
Market Set to Record Strong Growth Led by Advancements in Cardiac Biomarker Combinations
North America Corners Biggest Slice, Asia-Pacific to Dictate Market Momentum
Laboratory Testing Remains Gold Standard, POC Testing Rapidly Gains Traction
Table 1: Rising Importance of Cardiac Biomarkers in the overall POCT Market (2017): Percentage Share of Cardiac Biomarkers, Cholesterol, Coagulation, Infectious Diseases, Pregnancy, Self-monitoring Blood Glucose and Others (includes corresponding Graph/Chart)
Analysis by Type of Cardiac Biomarker Assay/Test
Emerging Markets, New Product Introductions Hold Key to Reviving Saturated Cardiac Troponin Assays Market
Competitive Landscape
Intense Competition among Players in the Cardiac Diagnostics Market
Leading Vendors Focus on Curtailing Turnaround Time of POC Cardiac Testing Kits
Cardiac Markers Point-Of-Care Testing (POC) Cardiac Testing Segment: Major Players and their Operating Brands
Other Recent Innovations
Lipid Biomarker Panel to Detect HfrEF
VectraplexECG System with CEB® Cardiac Electrical Biomarker
Cardiac Biomarkers on Smartphone
Stringent Regulations and Other Challenges
3. MARKET GROWTH DRIVERS, TRENDS & ISSUES
The Grim Reality of Mounting Economic and Social Burden of Cardiovascular Disease
Table 2: Prevalence of Heart Failure in Select Countries (includes corresponding Graph/Chart)
Population Explosion, Ballooning Geriatric Populace, Longer Life Expectancy Contributing to Rising Tide of CVDs
Table 3: Global Population Estimates (in Millions): 2017-2100 (includes corresponding Graph/Chart)
Table 4: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2
(includes corresponding Graph/Chart)
Table 5: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
Table 6: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
Table 7: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
Cardiac Biomarkers Hold the Key to Timely, Accurate Diagnosis & Prognosis
Commercialization of Novel Biomarkers to Drive Market Growth
Personalized Medicine, Companion Diagnostics Open Up Opportunities for Cardiac Biomarker Developers
Cardiac Biomarkers - A Powerful Tool for Patient Triaging
Cardiac Biomarkers Market Transitions from Mono-Marker to Multi-Marker Assays
Government Support Instrumental for Boosting Market Momentum
Secretoneurin Biomarker - a Potential Game Changer for Diagnosis of Cardiac Arrhythmias
High-Performance Techniques Drive Biomarker Discovery in Cardiology
Biomarkers for Acute Coronary Syndromes (ACS): A Leading Segment
Biomarkers - A Promising Diagnostic Tool for ACS
Biomarker Discovery for ACS to Undergo Significant Changes
Cardiac Biomarker Play Critical Role in Stroke Diagnosis
Cardiac Biomarkers to Find a Place in Neonatal Diagnosis and Treatment
Specificity, Sensitivity, Side Effects, Cost Concerns Hinder Market Growth
4. PRODUCT OVERVIEW
Cardiac Biomarkers
Necessity of a Cardiac Marker Assay Test
Cardiac Markers and Myocardial Infarction (MI)
Chain Reaction after an Event of MI
Action Plan after an Event of MI
Protocol for Conducting AMI Markers Tests
Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations
Cardiac Markers and Congestive Heart Failure (Chf)
Types of Cardiac Biomarkers
Major Cardiac Markers and their Properties
Creatine Kinase - The Gold Standard Losing Sheen
Isomers
Kinetics
Purpose of Test and When to Order
Evaluation
Points to remember
Cardiac Troponin
Troponin Tissue-Specific Subtypes
Other Diseases
Uses of Troponin Tests
New Advanced High-sensitivity (Hs) Cardiac Troponin Tests
Myoglobin
Purpose of Test and When to Order
Testing and Evaluation
Points of Caution
Natriuretic Peptides
BNP (B-type Natriuretic Peptide)
NT-proBNP (N-terminal proBNP)
Purpose of Tests and When to Order
Testing and Evaluation
Points to Remember
Introduction of BNP Test and the Changing Market Scenario in the Segment: A Review
Choosing the Right BNP and NT proBNP Assay Kit in the Market
Evolution of BNP and NT proBNP Market
NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with Reduced Kidney Function
Other Important Cardiac Biomarkers
Homocysteine
C-Reactive Protein
Plasminogen Activator Inhibitor-1
D-Dimer
Thrombus Precursor Protein
Galectin-3 Biomarker
Galectin-3: An Overview of Clinical Studies
Galectin-3: Overview of Clinical Studies in Cardiovascular Disease Diagnosis
Potential Future Cardiac Biomarkers
Location of Cardiac Biomarker Testing
Laboratory Cardiac Testing
Point-of-Care Cardiac Testing
5. COMPETITIVE LANDSCAPE
5.1 Focus on Select Players
Abbott Diagnostics, Inc. (USA)
Quidel Corporation (USA)
Beckman Coulter, Inc. (USA)
BG Medicine, Inc. (USA)
biomérieux SA (France)
Boditech Med Inc. (South Korea)
Labsystems Diagnostics OY (Finland)
LifeSign LLC (USA)
LSI Medience Corporation (Japan)
Ortho-Clinical Diagnostics, Inc. (USA)
Randox Laboratories Ltd. (UK)
Response Biomedical Corp. (Canada)
Roche Diagnostics (Switzerland)
Siemens Healthineers (USA)
Merck KGaA (Germany)
5.2 Product Introductions
Prevencio Introduces Clinical Trial Business, and Targets to Release LDT Cardio Test by Year End
Prothena Presents Novel Research on Cardiac Biomarker NT- proBNP in AL Amyloidosis at HFSA Annual Meeting
Fujirebio Europe Introduces the Lumipulse® G hs Troponin I and Lumipulse G Myoglobin immunoassays
5.3 Recent Industry Activity
Beckman Coulter Diagnostics Receives Clearance from Health Canada for Access hsTnI
Ortho Clinical Diagnostics and Sphingotec Announces Strategic Agreement Regarding Novel Biomarker
Abbott Acquires Alere Inc.
Bristol-Myers Squibb and Nordic Bioscience Collaborates for Fibrosis Biomarker Technology
6. GLOBAL MARKET PERSPECTIVE
Cardiac Biomarkers Testing By Geographic Region
Table 8: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 9: World Historic Review Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 10: World 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 2024 Cardiac Biomarkers Testing By Location of Testing (includes corresponding Graph/Chart)
Table 11: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 12: World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 13: World 14-Year Perspective for Cardiac Biomarkers in Laboratory Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
Table 14: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 15: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 16: World 14-Year Perspective for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 20247 (includes corresponding Graph/Chart)
7. REGIONAL MARKET PERSPECTIVE
7.1 The United States
A.Market Analysis
Current and Future Analysis
Statistics for Cardiovascular Diseases and Stroke, and Related Risk Factors and Costs in the US
Table 17: Prevalence of heart disease (All types) in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above
Table 18: Prevalence of Coronary Heart Disease in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above
Table 19: Prevalence of Hypertension in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and
Years & Above
Table 20: Prevalence of Stroke in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above
Table 21: US Total Annual Average Expenditure for Cardiovascular Diseases by Type of CVD (2015): Percentage Breakdown of Expenditure for Heart Disease, Hypertension, Stroke and Other CVDs (includes corresponding Graph/Chart)
B.Market Analytics
Cardiac Biomarkers Testing By Location of Testing
Table 22: The US Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 23: The US Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 24: The US 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.2 Canada
Market Analysis
Table 25: Canadian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 26: Canadian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 27: Canadian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.3 Japan
Market Analysis
Table 28: Japanese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 29: Japanese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 30: Japanese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4 Europe
A.Market Analysis
Current and Future Analysis
Growing Prevalence of Cardiovascular Disease Propels Growth of European Cardiac Biomarkers Market
Cardiac Markers in Primary Care Sector
B.Market Analytics
Table 31: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 32: European Historic Review Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 33: European 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
Cardiac Biomarkers Testing By Location of Testing
Table 34: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 35: European Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 36: European 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4.1 France
Market Analysis
Table 37: French Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 38: French Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 39: French 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4.2 Germany
Market Analysis
Table 40: German Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 41: German Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 42: German 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4.3 Italy
Market Analysis
Table 43: Italian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 44: Italian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 45: Italian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4.4 The United Kingdom
A.Market Analysis
Current and Future Analysis
B.Market Analytics
Table 46: The UK Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 47: The UK Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 48: The UK 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4.5 Spain
Market Analysis
Table 49: Spanish Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 50: Spanish Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 51: Spanish 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4.6 Russia
Market Analysis
Table 52: Russian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 53: Russian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 54: Russian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.4.7 Rest of Europe
Market Analysis
Table 55: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 56: Rest of Europe Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 57: Rest of Europe 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.5 Asia-Pacific
Market Analysis
Table 58: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 59: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2
(includes corresponding Graph/Chart)
Table 60: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
Cardiac Biomarkers Testing By Location of Testing
Table 61: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 62: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 63: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.5.1 China
Market Analysis
Table 64: Chinese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 65: Chinese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 66: Chinese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.5.2 India
Market Analysis
Table 67: Indian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 68: Indian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 69: Indian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.5.3 Rest of Asia-Pacific
Market Analysis
Table 70: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 71: Rest of Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 72: Rest of Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2
(includes corresponding Graph/Chart)
7.6 Latin America
Market Analysis
Table 73: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 74: Latin American Historic Review Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2
(includes corresponding Graph/Chart)
Table 75: Latin American 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for Brazil, and Rest of Latin America Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
Cardiac Biomarkers Testing By Location of Testing
Table 76: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 77: Latin American Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 78: Latin American 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.6.1 Brazil
Market Analysis
Table 79: Brazilian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 80: Brazilian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 81: Brazilian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
7.6.2 Rest of Latin-America
Market Analysis
Table 82: Rest of Latin-America Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 83: Rest of Latin-America Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 84: Rest of Latin-America 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2
(includes corresponding Graph/Chart)
7.7 Rest of World
Market Analysis
Table 85: Rest of World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 86: Rest of World Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2
through 2015 (includes corresponding Graph/Chart)
Table 87: Rest of World 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
8. COMPANY PROFILES
Total Companies Profiled: 39 (including Divisions/Subsidiaries - 44) The United States (21) Canada (1) Japan (1) Europe (15) - France (1) - Germany (2) - The United Kingdom (2) - Rest of Europe (10) Asia-Pacific (Excluding Japan) (6)
Download the full report: https://www.reportbuyer.com/product/5561790
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
SOURCE ReportBuyer